TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03721536

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: hemodynamic parameters
Description: vital signs on the monitor including heart rate, mean arterial pressure, peripheral oxygen saturation and End-tidal Carbon Dioxide

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: hemodynamic parameters
Description: vital signs on the monitor including heart rate, mean arterial pressure, peripheral oxygen saturation and End-tidal Carbon Dioxide

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: arterial blood gase
Description: Arterial blood gas including partial oxygen pressure and partial carbon dioxide pressure is an important routine investigation to monitor the acid-base balance of patients, effectiveness of gas exchange, and the state of their voluntary respiratory control.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: arterial blood gase
Description: Arterial blood gas including partial oxygen pressure and partial carbon dioxide pressure is an important routine investigation to monitor the acid-base balance of patients, effectiveness of gas exchange, and the state of their voluntary respiratory control.
Study: NCT04067232

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 4D-CT-scan
Description: Both forearms of the subjects with posttraumatic forearm impairment are scanned with a 4D-CT scanning technique, during forearm rotation.
Study: NCT01847755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen at 1.5 ATA (atmospheres absolute).
Description: Each patient will undergo 5 times-a-week Hyperbaric treatments to 1.5 ATA (atmospheres absolute) for up to 120 treatments. Treatment in hyperbaric chamber will be approximately 60 minutes. At specified intervals 40,80,120, patient will be assessed by Spect scan and cognitive assessments to provide outcome measure data. Pt will have a 3 month post treatment follow up assessment.
Study: NCT04266522

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive printed materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive printed materials
Study: NCT00714441

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer Automated Self-Management (CASM)
Description: CASM is a live and computer-assisted, low intensity, automated web and telephony based program that is directed at enhancing and sustaining diabetes self-management behavior over time. It provides education on the importance of healthy eating, physical activity and medication taking, and then asks patients to select an area for behavior change. At baseline patients will have a 45 minutes home visit to help them set goals and familiarize them with the website. A booster session is given at 20 weeks. Patients receive 8 ive phone calls over 12 months to support behavior change efforts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer Automated Self-Management (CASM)
Description: CASM is a live and computer-assisted, low intensity, automated web and telephony based program that is directed at enhancing and sustaining diabetes self-management behavior over time. It provides education on the importance of healthy eating, physical activity and medication taking, and then asks patients to select an area for behavior change. At baseline patients will have a 45 minutes home visit to help them set goals and familiarize them with the website. A booster session is given at 20 weeks. Patients receive 8 ive phone calls over 12 months to support behavior change efforts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer Automated Self-Management and Problem Solving Therapy (CAPS)
Description: Patients in the CAPS program receive all of the protocol included in the CASM program, and in addition receive a Problem Solving program. Problem solving is a process by which an individual attempts an adaptive solution to stressful, real life problem(s). At baseline there is a 45 minute home visit where the Counselor will introduce the patient to CASM and will go on to teach the patient about diabetes distress and PST. They will then generate a list of distress-related problems to teach the steps of PST. The steps of PST are: problem definition, goal setting, brain storming, decision making, action planning, and solution review. At 20 weeks there will be a booster session. Patients receive 8 live phone calls over 12 months to support behavior change efforts.
Study: NCT00633750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Tarceva will be given orally at a dose of 150 mg/day for 5-14 days. Patients are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TUNEL assay
Description: Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
Study: NCT02993770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic DCR
Description: Endonasal endoscopic technique as described by Wormold et al.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic DCR
Description: Endonasal endoscopic technique as described by Wormold et al.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External DCR
Description: External DCR
Study: NCT00633750

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Used to assess level of expression of genetic markers in pre-therapy and surgical specimens
Study: NCT02993770

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External DCR
Description: External DCR
Study: NCT00515931

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy (external beam photons)
Description: A cumulative radiation dose of 30 to 40 Gy is administered in 1.8 to 2.0 Gy fractions, 5 fractions per week, to the target lesion(s).
Study: NCT02088190

Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Description: Type of bariatric surgery

Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Description: Type of bariatric surgery
Study: NCT00633750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography
Description: Used to determine blood plasma levels of Erlotinib on the day of surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Used to determine blood plasma levels of Erlotinib on the day of surgery
Study: NCT03634280

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio taping
Description: In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
Study: NCT00940797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMMET-01
Description: 60 days: 30 days; dose 1050.6 mg per day (before dinner)+ 30 days; dose 1050.6 mg twice a day 30 more days (before breakfast ando before dinner)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 days: 30 days placebo once a day (before dinner) + 30 days twice a day (before breakfast and before dinner)
Study: NCT04338217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionator
Description: This is a functional appliance that is used to overcome the functional problems and to correct the open bite deformity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Removable Appliance with Posterior Bite Planes
Description: This is a one-jaw appliance that is used in conjunction with a tongue crib to control the faulty positions of the tongue and to help in closing the open bite through the use of posterior bite planes.
Study: NCT02196519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sylys Surgical Sealant
Study: NCT04580771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT05964712

Intervention type: PROCEDURE
Intervention: Medical surgery therapy
Description: De novo patients with acromegaly will undergo medical/surgical therapy of this disease, according to the guidelines of the Endocrine Society. In this population (group #1) morpho-functional examinations together with the evaluation of the stage of the disease, with serum dosage of GH and IGF-1, will be performed at baseline and at months 3, 6 and 12 after initiating the treatment.
Study: NCT04336124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)
Description: Patients will receive initial dose regimen: 400 mg of CVM-1118 ER Capsule per day (200 mg BID) in a 28-day cycle for 4 cycles.~Dose escalates from 400, 600, 800, to 1200 mg of CVM-1118 ER capsules with either BID or TID dosing.~A single-patient cohort per dose level (accelerated titration design) will be applied to the first two cohorts, 400 and 600 mg daily, and followed by the conventional 3+3 dose escalation design from the dose level of 800 mg/day.~If 2 or more patients experience a DLT, no further dose escalation will occur.
Study: NCT04580771

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101
Description: Given SC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT04802369

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic tests
Description: Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of arterial hypertension, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, non-invasive assessment for central arterial pressure waveform analysis and body mass analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Diagnostic tests
Description: Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of arterial hypertension, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, non-invasive assessment for central arterial pressure waveform analysis and body mass analysis.
Study: NCT01126918

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body Project
Description: Participants in this intervention attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
Study: NCT03123861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Patients randomized to this arm will receive 2 weeks of placebo post-operatively..
Study: NCT04668976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic pump and Codman catheter
Description: All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine (FUDR)
Description: Please see Detailed Description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Please see Detailed Description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Please see Detailed Description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11)
Description: Please see Detailed Description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Please see Detailed Description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-EGFR (Panitumumab or Cetuximab)
Description: Please see Detailed Description.
Study: NCT01126918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Project
Description: Participants in this intervention attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
Study: NCT04575740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAP
Description: Positive airway pressure to treat sleep apnea
Study: NCT02242695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluomizin vaginal tablets
Description: One vaginal tablet for 6 days and 1 placebo tablet on day 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canesten vaginal tablets
Description: one vaginal tablet for 7 days
Study: NCT01369498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: Simtuzumab administered intravenously over approximately 30 minutes every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: Simtuzumab administered intravenously over approximately 30 minutes every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: Simtuzumab administered intravenously over approximately 30 minutes every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: Simtuzumab administered intravenously over approximately 30 minutes every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: In Stage 2, participants will be on a stable dose of ruxolitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: In Stage 2, participants will be on a stable dose of ruxolitinib
Study: NCT04395378

Intervention type: DEVICE
Intervention: Continuous Glucose monitoring DEXCOM G6
Description: Continuous glucose monitoring during flight and normal living life
Study: NCT04178226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture
Description: The acupoints choose are (RN6) (RN4) (SP6) (PC6) (SP10) (SP4)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture
Description: The acupoints choose are (RN6) (RN4) (SP6) (PC6) (SP10) (SP4)
Study: NCT01219205

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal bevacizumab
Description: Intravitreal injections of bevacizumab were performed under sterile conditions in the operating room. a 27-gauge needle was inserted through the corneal limbus to withdraw 0.05 ml of aqueous humor and soften the globe. Then, 1.25 mg (0.05 ㎖) of bevacizumab was injected into the vitreous in the superior temporal quadrant with a 30-gauge needle that was inserted into the eye 3.5 mm from the limbus. The postoperative medications included topical antibiotics.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal bevacizumab
Description: Intravitreal injections of bevacizumab were performed under sterile conditions in the operating room. a 27-gauge needle was inserted through the corneal limbus to withdraw 0.05 ml of aqueous humor and soften the globe. Then, 1.25 mg (0.05 ㎖) of bevacizumab was injected into the vitreous in the superior temporal quadrant with a 30-gauge needle that was inserted into the eye 3.5 mm from the limbus. The postoperative medications included topical antibiotics.
Study: NCT01095042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: emotion
Description: Show that the susceptibility in the stress (recording of Heart Rate Variability;viewing films;...) is more important at the person affected by digestive pathologies (SII or IBD) in forgiveness than to unhurt subjects of pathologies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: emotion
Description: Show that the susceptibility in the stress (recording of Heart Rate Variability;viewing films;...) is more important at the person affected by digestive pathologies (SII or IBD) in forgiveness than to unhurt subjects of pathologies.
Study: NCT03320434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT-2761 0.5%
Description: Six drops in each eye over a 17 day period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT-2761 1%
Description: Six drops in each eye over a 17 day period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patanol
Description: Six drops in each eye over a 17 day period.
Study: NCT01019707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine, then Placebo
Description: As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine, then Placebo
Description: As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
Study: NCT03320434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pred-forte
Description: Four drops in each eye over a 3 day period.
Study: NCT01019707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, then Atomoxetine
Description: As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, then Atomoxetine
Description: As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
Study: NCT03174106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-Application
Description: Longterm follow-up after Cardiac rehabilitation With an Smartphone-Application
Study: NCT03273491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: daily self-weighing
Description: Participants are provided with a wifi-enabled scale and asked to weigh themselves daily, first thing in the morning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: daily temperature-taking
Description: Participants are provided with a wifi-enabled thermometer and asked to take their temperature daily, first thing in the morning.
Study: NCT03320434

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRT-2761 0%
Description: Six drops in each eye over a 17 day period.
Study: NCT00376363

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed implant
Description: placement of glaucoma drainage device to control intraocular pressure
Study: NCT01588236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose KYG0395
Description: 3 KYG0395 capsules tid (morning, midday, and evening)
Study: NCT00376363

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baerveldt implant
Description: placement of glaucoma drainage device to control intraocular press
Study: NCT04377698

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Fibrin
Description: regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
Study: NCT01588236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lower dose KYG0395
Description: 3 KYG0395 capsules 2 times a day (bid) (morning and evening) plus 3 capsules of placebo (midday)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules of placebo tid (morning, midday, and evening)
Study: NCT00578981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Osteoporosis Choice Decision Aid
Description: The provider will introduce the patient to the choice of bisphosphonates using the decision aid.
Study: NCT03196414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-138/BCMA/19/more
Description: Cyclophosphamide，Fludarabine，CART-138/BCMA /19/more cells Cyclophosphamide: 300 mg/m2 IV over 30 minutes on days -5 , -4,and -3; Fludarabine: 30 mg/m2 IV over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3 Biological: Anti-CD138/BCMA/CD19/more total CART cells 5x106- 100x106 CAR+ T cells per kg of recipient bodyweight
Study: NCT00438477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosulfan Blue
Description: At time of surgery, breast injected with 3-5 cc of isosulfan blue in subareolar or peritumoral position.
Study: NCT04266522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Receive direct physicist interactions to describe the technical aspects of the treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies